leadf
logo-loader
viewScancell Holdings PLC

Scancell Holdings awarded funds from Innovate UK for COVID-19 vaccine

Scancell Holdings' (LON:SCLP) Dr Cliff Holloway talks to Proactive London's Katie Pilbeam after being awarded funds from Innovate UK to produce a COVID-19 vaccine.

Holloway explains how the company is using their immunotherapies knowledge which is used in their cancer research projects to help with the COVID-19 drive.

Alongside this the company's lead drug, SCIB-1 to treat skin cancer has recently entered a phase II clinical trial in the UK.

Quick facts: Scancell Holdings PLC

Price: 15.5 GBX

LSE:SCLP
Market: LSE
Market Cap: £126.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Sunak extends furlough scheme and Moderna’s COVID-19 vaccine...

FTSE 100 bounced higher as traders waited for news of a potential Brexit outcome. London’s leading index rose 37 points to 6,588 in early trading, though the UK-focused FTSE 250 struggled. Chancellor Rishi Sunak has extended the furlough scheme by a month until the end of April. The decision...

on 18/12/20

2 min read